Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

Inclusion Criteria

• •1. Patients who meet AML according to WHO (2022) or AML and MDS/AML defined by ICC standards with IDH1 mutations detected by PCR or second-generation sequencing.
• •2. Age ≥14 years old, male or female.
• •3. The physical status assessment (ECOG-PS) of the Eastern Oncology Collaboration group was 0-2 points.
• •4. Fulfill the requirements of the following laboratory tests (performed within 7 days prior to treatment) :
• •1. Total bilirubin ≤ 1.5 times the upper limit of normal value (same age);
• •2. AST and ALT≤ 2.5 times the upper limit of normal value (same age);
• •3. Blood creatinine \< 2 times the upper limit of normal (same age);
• •4. Myocardial enzymes \< 2 times the upper limit of normal (same age);
• •5. Left ventricular ejection fraction \>50% by measure of echocardiogram (ECHO) Informed consent must be signed before the commencement of all specific study procedures, and is signed by the patient himself or his immediate family. Considering the patient\'s condition, if the patient\'s signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient\'s immediate family.